Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) with the Immune Tolerance Network (ITN), were published in an article today in The Lancet Diabetes & Endocrinology. The study enrolled 58 new-onset type 1 diabetic subjects ages 12-35.
ITN TrialShare Sees Public Usage Rise Following Publication of the First Manuscript with Embedded Links to the System
In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare (itntrialshare.org).
ITN Achieves Scientific Manuscript First - Provides Open, Interactive Access to Clinical Trial Data with New Publication: Rituximab Therapy Effective for ANCA-associated Vasculitis
In an article reporting the 18-month results of the Immune Tolerance Network’s (ITN) RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare
The Immune Tolerance Network’s (ITN’s) IMPACT Study, “Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children,” opened for enrollment today. This will be the first major study to examine whether oral immunotherapy can lead to durable, lasting tolerance to peanut among young peanut-allergic children. This study will be led by ITN investigator Wesley Burks, MD, Chair of the Department of Pediatrics at UNC Chapel Hill.
New Publication: AbATE Type 1 Diabetes Study Reveals Subset of Patients with Strong Response to Therapy
Primary results from the Immune Tolerance Network’s AbATE study (Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes) were published online today in Diabetes. The Phase II AbATE study, led by Kevan Herold, MD (Yale University), tested two doses of anti-CD3 given one year apart in new onset type 1 diabetics compared to control.
In a letter published recently in the Journal of Allergy and Clinical Immunology, Immune Tolerance Network (ITN) investigators describe the experience of the ITN’s GPAC study (Immunoprophylaxis of Allergic Disease) that aimed to test whether early intervention with a form of oral immunotherapy in at-risk young children could prevent the development of asthma.
ITN Type 1 Diabetes Data to be featured at the American Diabetes Association (ADA) Scientific Sessions
Data from three ITN type 1 diabetes trials will be featured during the “Clinical Trials of T Cell Therapeutics for Reversing Type 1 Diabetes” session at the Annual American Diabetes Association (ADA) Scientific Sessions in Chicago, IL. This session will take place on June 22 from 8:00am-10:00am CT.
New Publication: Clinical Outcomes of Remission Induction Therapy for Severe ANCA-Associated Vasculitis
In a manuscript published this week in Arthritis & Rheumatism, Immune Tolerance Network (ITN) investigators sought to better understand the distinction between patients who did and did not achieve the primary endpoint in the RAVE Study (Rituximab for the Treatment of ANCA-Associated Vasculitis and Microscopic Polyangiitis).
Sandy Feng, MD, PhD (University of California, San Francisco) will present 5-year follow-up data on tolerant patients from the Immune Tolerance Network’s (ITN’s) WISP-R study, “Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients” next week at the annual American Transplant Congress (ATC) meeting in Seattle, WA.
A letter published today in the New England Journal of Medicine reports on the long-term outcomes of patients from two ITN-sponsored combined kidney and bone marrow transplantation studies led by David H. Sachs, MD (Massachusetts General Hospital), Tatsuo Kawai, MD, PhD (Massachusetts General Hospital), Megan Sykes, MD (Columbia University) and A. Benedict Cosimi, MD (Massachusetts General Hospital).